Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.66 |
| ▸ | PIM1 | P11309 | 4/20 | 0.49 |
| ▸ | CDC7 | O00311 | 3/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30117918 | 1.00 | KMT2A (0.66) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL22006945 | 0.87 | KMT2A (0.49) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL1854586 | 0.84 | PIM1 (0.49) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL4573298 | 0.84 | ALDH1A1 (0.62) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL4593418 | 0.84 | KMT2A (0.66) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL30634511 | 0.84 | PIM1 (0.49) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL24388208 | 0.80 | PIM1 (0.54) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL4593581 | 0.80 | HRH4 (0.62) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL29565166 | 0.80 | PIM1 (0.54) | KMT2AALDH1A1LMNAGPR55PIM1 | |
| SCHEMBL15766371 | 0.80 | KMT2A (0.61) | KMT2AALDH1A1LMNAGPR55PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040549-B1 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | claimed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | claimed |
| EP-2040549-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-01 | — | — | EP | claimed |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | claimed |
| WO-2008008359-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | WO | claimed |
| US-12364159-B2 | Organic compound, light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-07-15 | — | — | US | disclosed |
| CN-119836133-A | Light-emitting element, display device, electronic device, organic compound, and lighting device | 株式会社半导体能源研究所 | 2025-04-15 | — | — | CN | disclosed |
| US-12252496-B2 | Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-03-18 | — | — | US | disclosed |
| CN-112189265-B | Light-emitting element, display device, electronic device, organic compound, and lighting device | 株式会社半导体能源研究所 | 2025-02-14 | — | — | CN | disclosed |
| US-20240423005-A1 | LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12082429-B2 | Light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-12030890-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | MERCK PATENT GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| EP-2040549-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035668-A1 | FACILE ASSEMBLY OF FUSED BENZOFURO-HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2008008359-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252496-B2 | Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device | TPMT, POU5F1, CCND1 | KMT2A 1571/4885ALDH1A1 105/4885LMNA 4296/4885 |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | KMT2A 1207/4885ALDH1A1 2682/4885LMNA 4871/4885 |
| US-20090076268-A1 | Facile assembly of fused benzofuro-heterocycles | BICRA, DDC, DDT | KMT2A 1540/4885ALDH1A1 739/4885LMNA 4384/4885 |
| US-12030890-B2 | Compounds with diazadibenzofurane or diazadibenzothiophene structures | DDT, ESD, DBF4 | KMT2A 1118/4885ALDH1A1 722/4885LMNA 4452/4885 |
| US-12364159-B2 | Organic compound, light-emitting device, light-emitting apparatus, electronic device, and lighting device | CYP2C19, CYP2C9, AOX1 | KMT2A 2534/4885ALDH1A1 90/4885LMNA 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.